A Controlled, Randomized, First-In-Human Study of AP31969 Investigating Single and Multiple Ascending Doses and the Effect of Food in Healthy Subjects
Latest Information Update: 06 Nov 2024
At a glance
- Drugs AP-31969 (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions; First in man
- Sponsors Acesion Pharma
Most Recent Events
- 04 Nov 2024 Planned End Date changed from 17 Sep 2024 to 27 Feb 2025.
- 04 Nov 2024 Planned primary completion date changed from 17 Sep 2024 to 27 Feb 2025.
- 06 May 2024 Planned End Date changed from 24 May 2024 to 17 Sep 2024.